Lupin . Faces Decline in Stock Performance, MarketsMOJO Calls for 'Hold' Rating

Lupin ., a leading pharmaceutical company in the largecap industry, has recently faced a decline in its stock performance. On October 23, 2024, the company's stock saw a decrease of -3.06%, underperforming the sector by -1.83%. This has led to a 'Hold' call by MarketsMOJO for the stock.

In the past three days, Lupin . has been on a downward trend, with a fall of -5.09% in returns. On the same day, the stock touched an intraday low of Rs 2073.8, showing a decrease of -2.73%. However, the stock's moving averages are still higher than the 100-day and 200-day averages, but lower than the 5-day, 20-day, and 50-day averages.

In comparison to the Sensex performance, Lupin .'s 1-day performance is -2.58%, while the Sensex only saw a decrease of -0.16%. Similarly, in the past month, Lupin .'s performance has been -4.94%, while the Sensex has seen a decline of -5.70%.

Despite the recent decline in stock performance, Lupin . remains a strong player in the pharmaceutical industry. With its largecap size, the company has a strong presence in the market and continues to provide quality products to its customers. Investors are advised to hold their positions and monitor the company's performance in the coming days.